

# The dual-specificity phosphatase JSP1 regulates neutrophil adhesion *via* integrin-SRC signaling in vascular inflammation

Received for publication, September 17, 2025, and in revised form, February 11, 2026 Published, Papers in Press, March 16, 2026  
<https://doi.org/10.1016/j.jbc.2026.111369>

Li Li<sup>1</sup> and Nicholas K. Tonks<sup>1\*</sup>

From the Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA

Reviewed by members of the JBC Editorial Board. Edited by Alex Tokor

The c-JUN N-terminal kinase (JNK) signaling pathway plays an important role in regulating the innate immune response. Immune signaling is governed by the coordinated activity of protein kinases counter-balanced by protein phosphatases; however, the importance of the latter family of enzymes is less well understood. c-JUN N-terminal kinase (JNK)-stimulatory phosphatase 1 (JSP1, also known as DUSP22) has been implicated as a positive regulator of JNK signaling, yet its role in innate immunity is not clear. Using a mouse model of the local Shwartzman reaction, we show that JSP1 is essential for LPS-TNF- $\alpha$ -induced vascular injury. JSP1-knockout mice exhibited reduced vascular hemorrhage. Neutrophil depletion and adoptive transfer experiments confirmed that JSP1-expressing neutrophils mediate this injury. JSP1 was not required for neutrophil development or surface receptor abundance but was essential for integrin activation and adhesion. Reduced SYK and HCK phosphorylation in JSP1-knockout neutrophils is consistent with a mechanism involving impaired integrin-SRC signaling. These findings establish JSP1 as a key regulator of neutrophil-driven vascular inflammation.

Mitogen-activated protein kinase (MAPK) signaling pathways are critical regulators of cellular responses to a wide range of extracellular stimuli, including inflammatory cytokines and environmental stress. These pathways orchestrate key biological processes by relaying signals from the cell surface to the nucleus, ultimately influencing gene expression and cellular behavior (1, 2). Among the MAPK cascades, the c-JUN N-terminal kinase (JNK) pathway is particularly responsive to pro-inflammatory cytokines such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), which can be induced by lipopolysaccharide (LPS), and plays a pivotal role in inflammatory and stress responses.

Given the profound impact of MAPK signaling on cellular physiology, tight regulation of MAPK activity is essential. This regulation is achieved at several levels. Activation of MAPKs is coordinated in kinase cascades, the assembly of which is regulated by scaffold proteins, and counterbalanced by the

action of protein phosphatases (3, 4). Members of the protein tyrosine phosphatase (PTP) family, including dual-specificity phosphatases (DUSPs), regulate MAPKs by removing phosphate groups from both threonine and tyrosine residues within their activation loops (4–6), which suppresses MAPK function and serves to switch off signaling. Furthermore, beyond direct effects on MAPKs themselves, the activation state of MAPK signaling modules can be influenced by dephosphorylation of other critical components in the cascade as well as by the organization of cascade components into ordered complexes.

JNK-stimulatory phosphatase 1 (JSP1), also known as DUSP22, JKAP, or VHX, is a member of the DUSP family that is characterized by intrinsic phosphatase activity but lacking the cdc25-homology domain typically required for substrate docking of the MAPKs themselves (7–9). Unlike most DUSPs that inactivate MAPKs, JSP1 has been shown to act as a positive regulator of the JNK pathway (7, 8). Interestingly, JSP1, and VHY/DUSP15 (10), are unique among the members of the PTP family in being myristoylated at Gly2 in the N-terminus, a modification that is required for its ability to activate JNK signaling and apoptosis (11). Although it was also suggested initially that DUSP22 dephosphorylated ERK (9), a more recent study confirmed the ability of DUSP22 to activate JNK, suggesting also that it may serve as a scaffold to promote signaling through a ASK1-MKK7-JNK pathway (12).

A variety of substrates have now been identified for JSP1/DUSP22 that expand our understanding of its biological influence. In general terms, JSP1/DUSP22 has been associated with regulation of the epithelial-to-mesenchymal transition (EMT), through effects on SMAD and MAPK signaling pathways (13), as well as control of cell migration, through dephosphorylation and inactivation of focal adhesion kinase, FAK (14). Dephosphorylation of FAK also underlies the ability of JSP1 to attenuate MASH (metabolic dysfunction-associated steatitic liver disease) and HCC (hepatocellular carcinoma) (15). Overexpression of JSP1 in 293T cells reduced IL-6-induced phosphorylation of STAT3 at tyrosine 705, suggesting a negative regulatory role in IL-6/STAT3-mediated signaling (16). JSP1 also negatively regulates estrogen receptor- $\alpha$  (ER- $\alpha$ )-mediated transcription by dephosphorylating ER- $\alpha$  at serine 118 (17).

JSP1 has also been implicated in the etiology of important disease states. Knockdown of JSP1, or pharmacological

\* For correspondence: Nicholas K. Tonks, [tonks@cshl.edu](mailto:tonks@cshl.edu).

Present address for Li Li: Department of Biology, Chemistry and Environmental Sciences, Molloy University, 1000 Hempstead Ave, Rockville Center, NY 11570.

## JSP1 in vascular inflammation

inhibition of its activity, in multiple models of muscle wasting, suppressed JNK activation and prevented muscle loss *via* down regulation of FOXO3a, a master transcription factor promoting muscle catabolism (18). A tumor suppressor function has been identified in lung cancer. The exosomal micro-RNA miR-1228-5p, which is upregulated in small cell lung cancer, inhibits expression of JSP1 thereby facilitating cancer cell growth and metastasis (19). In non-small cell lung cancer (NSCLC) down-regulation of JSP1 coincides with decreased survival; it has been reported that JSP1 dephosphorylates AKT, underlying inhibitory effects on cell viability and migration (20). In lung adenocarcinoma, JSP1 suppresses tumorigenesis by inhibiting EGFR signaling (21); similar observations were reported in prostate cancer (22). In addition, JSP1 is an important immune regulator. In T cell receptor (TCR) signaling, JSP1 negatively regulates T cell activation by dephosphorylating LCK at Y394 (23) and modulates LCK stability through dephosphorylation-induced proteasome degradation of E3 ligase UBR2, an upstream activator, to switch off TCR signaling (24). Downregulation of JSP1 has also been linked to inflammatory disorders. Ablation of JSP1 promotes atherosclerosis through regulation of ERK and NF- $\kappa$ B pathways (25). Reduced JSP1 levels have also been observed in T cells of patients with ankylosing spondylitis (26) and systemic lupus erythematosus (27), in the serum of sepsis patients (28), and in synovial tissue and serum of rheumatoid arthritis patients (29). Similarly, JSP1 levels are decreased in patients with fatty liver disease (15). Collectively, these findings suggest that JSP1 may serve as a biomarker for inflammatory diseases and a potential indicator of disease prognosis.

Such observations underscore the cell- and context-specific functions of JSP1 in immune and metabolic signaling; however, its role in innate immune responses, particularly in vascular inflammation, remains poorly understood. To address this gap, we investigated the function of JSP1 in a mouse model of vascular inflammation, the local Shwartzman reaction (LSR). The LSR is elicited by sequential exposure to bacterial lipopolysaccharide (LPS) followed by tumor necrosis factor-alpha (TNF-alpha), leading to robust activation of JNK signaling and local intravascular inflammation (30, 31). This response is characterized by neutrophil infiltration, cytokine release, endothelial activation, and vascular permeability changes, making it a powerful experimental tool for dissecting molecular mechanisms of inflammation-driven vascular injury. Our study reveals that JSP1 is essential for neutrophil-mediated vascular injury by regulating integrin-dependent adhesion through SRC family kinase signaling. These findings uncover a novel role for JSP1 in neutrophil activation and suggest its potential as a therapeutic target in inflammatory vascular diseases.

## Results

### JSP1 is required for LPS-induced vascular injury

JSP1 was originally identified and characterized as a selective activator of the MAPK JNK in cell co-transfection assays (7, 8). Members of the JNK group are predominantly

activated after exposure of cells to proinflammatory cytokines. Therefore, to investigate further the physiological role of JSP1, we utilized a modified mouse model of the LSR (32). In this model, consecutive injections of LPS and TNF-alpha activate JNK signaling, which provides an opportunity to explore the functions of JSP1 in the host response to inflammation stimuli.

Wild-type (WT) and JSP1-knockout (KO) mice were subjected to subcutaneous injections of LPS, followed by TNF-alpha, to enhance the inflammatory response. Notably, KO mice exhibited reduced inflammatory reactions compared to their WT counterparts, as illustrated by decreased vascular permeability (Fig. 1). These observations suggest that JSP1 may play a crucial pro-inflammatory role in LPS-induced vascular injury, potentially by modulating signaling pathways involved in immune activation.


### JSP1-dependent neutrophils drive LPS-TNF-alpha-induced vascular injury

In the LSR model, neutrophil infiltration at the LPS-TNF-alpha injection site has been well-documented (32, 33). To identify the primary cell type responsible for vascular inflammation, we selectively depleted neutrophils in wild-type mice using Gr-1 antibodies before administering LPS-TNF-alpha. In neutrophil-depleted mice, no signs of vascular injury were observed, as illustrated by the absence of vascular hemorrhage (Fig. 2A). These results confirm that neutrophils are essential mediators of LPS-TNF-alpha-induced vascular injury.

To investigate further the role of JSP1 in neutrophil-mediated inflammation, we performed adoptive transfer experiments using neutrophils from different genetic backgrounds. Intravenous transfer of JSP1-knockout neutrophils into WT mice significantly diminished vascular injury upon LPS-TNF-alpha challenge, suggesting that JSP1-knockout neutrophils have a reduced pro-inflammatory capacity. Conversely, transferring WT neutrophils into KO mice restored vascular injury to levels comparable to those observed in WT mice (Fig. 2B), demonstrating that the presence of JSP1-expressing neutrophils is sufficient to drive inflammation and vascular damage. These observations establish that neutrophils are the mediators of vascular injury in the LSR model and that their pro-inflammatory function is JSP1-dependent. This suggests that JSP1 plays a critical role in neutrophil activation or in signaling pathways that contribute to LPS-TNF-alpha-induced vascular permeability and inflammation.

### JSP1 did not affect neutrophil maturation or CD11b expression


To determine whether JSP1 influences neutrophil maturation or surface marker expression, we performed flow cytometry analysis on bone marrow-derived mature neutrophils from WT and KO mice. The analysis revealed no significant difference in the quantity of mature neutrophils between the two genotypes, indicating that JSP1 is not required for neutrophil development or homeostasis (Fig. S1A).



**Figure 1. JSP1 was required for LPS-induced vascular injury.** *A*, schematic representation of the injection regimen for the LSR mouse model. *B*, macroscopic appearance of dorsal skin in mice injected with PBS or LPS-TNF-alpha. *C*, the degree of hemorrhage in the WT and KO mice was quantified by densitometry analysis of skin samples treated with either PBS or LPS injection. Each dot represents the ratio of the degree of hemorrhage obtained from a pair of mice (LPS-TNF-alpha-treated over PBS-treated). Data are presented as mean  $\pm$  SD. Statistical analysis for *C* by unpaired two-tailed Student's *t* test; \*\**p* < 0.01, based on three pairs of mice per group. WT, wild-type; KO, JSP1-knockout. Scale bar: 2 mm.

Additionally, we assessed the expression of integrin subunit CD11b, also known as integrin alpha M, which is a key surface marker involved in neutrophil adhesion and recruitment. The results showed that CD11b expression levels were comparable between WT and JSP1-knockout neutrophils (Fig. S1B), suggesting that JSP1 does not regulate the surface expression of this integrin.

These findings indicate that the pro-inflammatory role of JSP1 in neutrophil-mediated vascular injury is not due to differences in neutrophil abundance or CD11b expression. Instead, JSP1 likely influences neutrophil function through intracellular signaling mechanisms rather than through changes in neutrophil maturation or integrin expression.



**Figure 2. JSP1-dependent neutrophils were responsible for LPS-TNF-alpha-induced vascular injury.** *A*, macroscopic appearance of dorsal skin in WT mice injected subcutaneously with PBS or LPS-TNF-alpha, which received either anti-IgG or anti-Gr-1 antibody 48 h before PBS or LPS-TNF-alpha challenge. *B*, macroscopic appearance of dorsal skin in mice that were intravenously injected with bone marrow neutrophils ( $2 \times 10^6$ ) isolated from either JSP1-knockout (KO to WT) or WT mice (WT to KO or WT to WT). The degree of hemorrhage in mice was quantified by densitometry analysis of skin samples treated with either PBS or LPS injection. Each dot represents the ratio of the degree of hemorrhage obtained from a pair of mice (LPS-TNF-alpha-treated over PBS-treated). Data are presented as mean  $\pm$  SD. Statistical analysis for *A* by unpaired two-tailed Student's *t* test and for *B* by one-way ANOVA followed by Dunnett's multiple comparisons test, with WT to WT as the control group; \**p* < 0.05; \*\**p* < 0.01, based on three pairs of mice in each group. KO, JSP1-knockout; WT, wild-type. Scale bar: 2 mm.


### JSP1 promoted neutrophil adhesion via integrin activation

Integrin activation on the neutrophil surface facilitates neutrophil adhesion (33, 34). To examine the role of JSP1 in integrin-mediated neutrophil adhesion, neutrophils were plated on poly-RGD-coated surfaces, which function as integrin ligands and cross-linkers that partially mimic extracellular matrix interactions. Neutrophils isolated from JSP1-knockout mice exhibited significantly reduced adhesion compared with WT neutrophils (Fig. 3). Notably, because not all integrins recognize the RGD motif—only approximately half of the  $\sim 20$  known integrins bind RGD-containing ligands (35)—RGD-coated surfaces do not engage the full complement of integrins expressed on neutrophils. This limitation likely explains the overall reduced level of adhesion observed even in WT neutrophils on RGD-coated plates. Together,

these data indicate that JSP1 is required for optimal integrin activation and adhesion in neutrophils, supporting a role for JSP1 in regulating integrin-dependent pro-inflammatory responses during vascular injury.

### SRC family kinase activation is essential for LPS-TNF-alpha-induced vascular injury

In neutrophils, SRC family kinases HCK, FGR, and LYN are critical regulators of integrin signaling. Consistently, *Hck*<sup>-/-</sup>*Fgr*<sup>-/-</sup>*Lyn*<sup>-/-</sup> mice exhibit markedly reduced neutrophil adhesion (34). The spleen tyrosine kinase SYK associates with SRC family kinases specifically in adherent neutrophils bound to fibrinogen (36). Moreover, both HCK and SYK have been implicated as key mediators of neutrophil activation in the LSR mouse model (33). Together, these findings suggest that



**Figure 3. Integrin engagement activates JSP1-dependent neutrophil adhesion.** Neutrophils from either WT or JSP1-knockout mice were plated on poly-RGD-peptide-coated plates to promote integrin engagement. After 15 min of incubation, adherent neutrophils were quantified. Each dot represents the total number of adherent cells observed under a 20 × objective lens. Data are presented as mean ± SD. Statistical analysis by two-way ANOVA, Sidak multiple comparisons test; *p* value reflects Sidak-adjusted comparisons between genotypes at each poly-RGD concentration; \*\**p* < 0.01, *n* = 9 fields at 200 × magnification. Data are representative of three independent experiments.

activation of SRC family kinases is essential for mediating the inflammatory response and vascular damage following LPS–TNF- $\alpha$  stimulation.

To test directly the role of SRC family kinases in neutrophil adhesion and vascular injury, we used the SRC tyrosine kinase inhibitor PP2 (37). Treatment of WT neutrophils with PP2 markedly reduced their adhesion to fresh mouse serum-coated plates (Fig. 4A). Furthermore, co-injection of PP2 with LPS and TNF- $\alpha$  in WT mice resulted in a marked attenuation of vascular injury as demonstrated by decreased vascular permeability and reduced inflammatory responses (Fig. 4B). These observations highlight SRC family kinase activation as critical for neutrophil adhesion and subsequent vascular injury in the LSR mouse model.

### JSP1 positively regulates SYK and HCK phosphorylation in integrin-activated neutrophils

To investigate the molecular mechanism by which JSP1 modulates neutrophil adhesion and activation, we examined the phosphorylation status of key signaling proteins involved in integrin-mediated responses. SYK, a critical tyrosine kinase in integrin signaling, exhibited reduced activation in integrin-stimulated JSP1-knockout neutrophils compared to WT neutrophils (Fig. 5A). Similarly, decreased phosphorylation of HCK was observed in JSP1-knockout neutrophils upon integrin activation (Fig. 5B). Interestingly, and consistent with its function as a protein phosphatase, we observed that JSP1 was able to dephosphorylate the C-terminal inhibitory phosphorylation site in HCK (Fig. 5C).

Overall, these observations are consistent with an important role of JSP1 in fine-tuning neutrophil activation by upregulating SYK and HCK phosphorylation, thereby influencing integrin-mediated adhesion and inflammatory responses.

## Discussion


Members of the PTP family are critical regulators of signaling pathways through their ability to dephosphorylate varied substrates. Within that family, classical DUSPs, such as those targeting MAPKs, typically function as negative regulators that can influence the intensity and duration of signaling by dephosphorylating and inactivating ERK, JNK, or p38 (1–6). Conversely, protein phosphatases can also function to switch on signaling. For example, *cdc25* acts positively to promote cell-cycle progression by dephosphorylating inhibitory residues on cyclin-dependent kinases (CDKs) (38). These contrasting activities highlight the dual potential of phosphatases to either dampen or amplify signaling events depending on the cellular context and substrate specificity. In this study, we highlight a further example of a phosphatase that may act positively to promote a signaling response.

Since its identification as a unique DUSP capable of activating JNK signaling (7, 8), JSP1 (DUSP22) has garnered attention as a regulator of diverse physiological and pathophysiological processes, including immunity and cancer. Structural studies revealing a shallow and accessible catalytic cleft, consistent with its capacity to act on multiple substrates and pathways (39). Our findings extend these observations by demonstrating that JSP1 also plays a pivotal role in neutrophil adhesion and inflammatory vascular injury.

LSR is an animal model of the innate immune response, including JNK-driven vascular inflammation (30, 31). This is a two-stage model. Firstly, a priming injection of endotoxin (LPS) sensitizes the innate immune system by recruiting inflammatory cells, such as neutrophils, to the injection site. A second injection of TNF- $\alpha$ , or endotoxin to activate release of inflammatory cytokines such as TNF- $\alpha$ , triggers an acute inflammatory response in which initiation of JNK signaling cascades is of particular importance (31, 40). In this study, we have established that systemic deletion of JSP1 protects against LPS/TNF- $\alpha$ -induced vascular injury in this model. This protection correlates with impaired neutrophil adhesion and reduced activation of integrin signaling, implicating JSP1 as a key upstream regulator in the inflammatory cascade. Our adoptive transfer experiments reveal a cell-intrinsic requirement for JSP1 in neutrophils, underscoring the fact that its pro-inflammatory role is directly attributable to neutrophil function and is not secondary to systemic alterations. Mechanistically, neutrophils lacking JSP1 displayed diminished phosphorylation of HCK and SYK—critical kinases in the integrin signaling pathway. These data suggest that JSP1 facilitates integrin-mediated signaling in neutrophils, possibly enabling the assembly or stabilization of signaling complexes at adhesion sites and strengthening the notion that JSP1 operates as a cell-specific regulator of innate immunity.

The ability of JSP1 to activate SRC family kinases illustrates a further example of the exquisite specificity of PTP family members in their recognition of target substrates and their biological functions. SRC family kinases are tightly regulated by two opposing phosphorylation events – an inhibitory site


## JSP1 in vascular inflammation



**Figure 4. PP2, an inhibitor of SRC family kinases, attenuated neutrophil adhesion and LPS-induced vascular inflammation in WT mice.** *A*, quantitative analysis of TNF-alpha-stimulated WT neutrophil adhesion to fresh mouse serum-coated plates in the presence of SRC family kinase inhibitor PP2. Neutrophils were incubated in plates for 40 min, followed by washing and microscopic counting of attached neutrophils across 9 fields at 200x magnification. Each dot represents the total number of adherent cells observed under a 20 × objective lens. *B*, morphological examination of dorsal skin in WT mice subcutaneously injected with either PBS, LPS + TNF-alpha, or LPS + TNF-alpha along with the SRC tyrosine kinase inhibitor PP2. *C*, the degree of hemorrhage in mice was quantified by densitometry analysis of skin samples treated with PBS, LPS + TNF-alpha, or LPS + TNF-alpha + PP2 injection. Each dot represents the ratio of the degree of hemorrhage obtained from a pair of mice (Treated over PBS-injected). Data are presented as mean ± SD. Statistical analysis for *A* and *C* by one-way ANOVA, Dunnett's multiple comparisons test; \*\* $p < 0.01$ , based on three pairs of mice in each group. Scale bar: 2 mm.

of tyrosine phosphorylation in the C-terminus (Tyr527 in SRC) and the activating autophosphorylation site (Tyr416 in SRC). Phosphorylation of the C-terminal site by C-terminal SRC Kinase (CSK) promotes a closed, inactive conformation; dephosphorylation of this site allows SRC to adopt an open

conformation, to autophosphorylate Tyr 416 in the activation loop, switch on activity, and promote signaling. Therefore, depending upon which site they dephosphorylate, PTPs can either promote or inhibit signaling through regulation of SRC activity. Furthermore, there are examples of PTPs, such as



**Figure 5. Tyrosine phosphorylation of SYK and HCK is down-regulated in integrin-activated JSP1-knockout neutrophils.** *A*, lysates of WT or KO neutrophils, either plated on a poly-RGD-coated surface (+ integrin activation) or suspended (- integrin activation) in assay media, were prepared after 15-min incubation and immunoprecipitated with an anti-SYK antibody. The resulting immunoprecipitates were analyzed to assess the level of SYK tyrosine phosphorylation with anti-pSYK Y323 antibody. *B*, lysates of neutrophils treated as described in (*A*) were also immunoprecipitated with either an anti-phosphotyrosine (4G10) antibody or an anti-HCK antibody to evaluate the tyrosine phosphorylation of HCK and overall tyrosine phosphorylation levels. *C*, JSP1 activates HCK by dephosphorylating the negative regulatory tyrosine 522. Lysates of 293T cells transfected with either JSP1 WT, JSP1 CS (inactive mutant), or vector control, along with flag-tagged HCK and CSK, were immunoprecipitated with an anti-HCK antibody. The immunoprecipitates were then analyzed by immunoblotting with anti-pHCK Y522 to detect phosphorylation at tyrosine 522, and with anti-FLAG to confirm the expression of the transfected constructs. Each immunoblot was reproduced three times with similar results. KO, JSP1-knockout; WT, wild-type.

RPTP $\alpha$  and RPTP $\gamma$  (41, 42), which can both inhibit and activate SRC depending upon context, including localization and the state of phosphorylation of the activating and inhibiting sites. Our data highlights that JSP1 is another such example. It has been reported that JSP1 may inactivate LCK by dephosphorylating Tyr 394 (23), leading to suppression of T cell-mediated immunity. In contrast, we now demonstrate that, upon acute stimulation, such as exposure to bacterial lipopolysaccharide (LPS), JSP1 exhibits pro-inflammatory activity to help resolve the immediate challenge. This dual role is reminiscent of the general dynamics of inflammatory

responses —beneficial and protective in the short term, but potentially detrimental when sustained over time.

The JNK signaling pathway can be activated in response to a wide array of stimuli, from cytokines to tissue damage. In turn, this underlies fundamental aspects of the inflammatory response, from recruitment and activation of immune cells to engaging the adaptive immune system. Furthermore, disruption of JNK-dependent signaling has been implicated in a range of major diseases, including vascular diseases. The development of approaches to target JNK activation in such contexts holds major therapeutic potential. By expanding the functional repertoire of JSP1 to the modulation of neutrophil signaling and vascular inflammation, our study illustrates a new potential mechanism to achieve this. The identification of JSP1 as a positive regulator of SRC family kinase activation in neutrophils provides a mechanistic link between phosphatase activity, integrin signaling, and vascular injury. Importantly, these insights position JSP1 as a potential therapeutic target for conditions characterized by excessive neutrophil activation and vascular damage, including sepsis, autoimmune vasculitis, and ischemia-reperfusion injury. Future studies will be needed to determine the precise molecular mechanism by which JSP1 promotes HCK and SYK activation, balancing direct dephosphorylation of inhibitory residues in the SRC family kinases with indirect effects on scaffolding functions, and to define potential links between SRC and JNK activation in this system (43). Furthermore, there have been reports of the identification of two compound inhibitors of JSP1 activity (18, 44); it will be important to assess whether selective inhibition of JSP1 with small-molecule drug candidates can attenuate neutrophil-driven pathology in clinically relevant models.

In conclusion, our findings reveal a previously unrecognized role of JSP1 in neutrophil adhesion and vascular inflammation through the regulation of SRC family kinase signaling. By bridging phosphatase activity with innate immune function, this work highlights JSP1 as a novel and promising target for therapeutic modulation of inflammatory vascular injury.

## Experimental procedures

### Materials

Reagents and antibodies are summarized in Table 1.

### Mice

The mouse studies were performed in accordance with procedures approved by the IACUC at CSHL and NIH Guide for Care and Use of Laboratory Animals.

### JSP1 knockout mice generation

Two-to three-month-old mice were used. C57BL/6 mice were purchased from Taconic Farms Inc., NY. JSP1 knockout mice were generated by targeted deletion of Exon III of the JSP1 gene and backcrossed at least 10 times to the C57BL/6 background (CEPTYR Inc.). Genotype of all JSP1 knockout

## JSP1 in vascular inflammation

**Table 1**  
Reagents and antibodies

Reagent/Antibody	Source	Product/Catalog no.
LPS	Sigma-Aldrich	L6529, 1 mg
TNF-alpha	Sigma-Aldrich	T5944, 10 µg
PP2	Sigma Aldrich	529573
10xHBSS, Ca <sup>2+</sup> /Mg <sup>2+</sup> -free	ThermoFisher Scientific	14185052
100% Percoll	Sigma-Aldrich	P1644
Nyco-prep	Accurate Chemical & Scientific Corp.	AN1106865
RBC lysis buffer	Sigma-Aldrich	R7757
poly-RGD peptides	Sigma Aldrich	F5147-1 mg
Protein G agarose bead slurry	Cell Signaling	37478
pSYK (Y323) antibody	Cell Signaling	2715
HCK antibody	Santa Cruz Biotechnology	sc-1428
4G10 antibody	Millipore	05-321
pHCK (Y522) antibody	Thermo Fisher Scientific	44-912

mice was confirmed by PCR analysis of DNA isolated from tail biopsies at the CSHL Animal Facility.

### Mouse model of LSR

The physiological functions of JSP1 were explored in the mouse model of Local Shwartzman Reaction (LSR, 30–32).

### Anesthesia and mouse preparation for injection

In brief, on the first day of injection, mice were marked and anesthetized in an isoflurane chamber. Anesthetized mice were rubbed with Nair Hair Removal Cream on their dorsal hair and left in the isoflurane chamber with padding for at least 5 min. Then the creamed hair was removed by a soapy warm water-immersed gauze followed by a regular tap water-immersed one. The exposed skin was sterilized by 70% ethanol.

### Subcutaneous injection of LPS and TNF $\alpha$

On Day 1, mice were injected subcutaneously on the dorsal skin with 80 µl of either sterile PBS or LPS (1 mg/ml). On Day 2, 80 µl of either sterile PBS or TNF-alpha (0.2 µg) was administered subcutaneously at the same dorsal site as the Day 1 injection.

### Macroscopic examination of skin lesion was done on day 3

Mice were anesthetized in an isoflurane chamber with padding and macroscopically examined for vascular inflammation. Pictures were taken with a Canon digital camera. The relative levels of hemorrhage were quantified by densitometry of macroscopic images using ImageJ software (National Institutes of Health).

### Neutrophil isolation

Preparation of bone-marrow-derived mouse neutrophils was described previously (32). In brief, mouse bone marrow cells flushed from femurs and tibias were resuspended in 3 ml Ca<sup>2+</sup>/Mg<sup>2+</sup>-free Hank's balanced salt solution (HBSS) containing 1% BSA, which were loaded onto a discontinuous density gradient containing 3 ml of a 72% Percoll under 3 ml of Nyco-prep. After centrifugation at 1000 × g for 20 min (without brake when slowing down) at room temperature,

cells at the interface between the 72% Percoll and Nyco-prep were collected and washed with Ca<sup>2+</sup>/Mg<sup>2+</sup>-free HBSS. The cell pellet was resuspended in 1 ml of RBC lysis buffer and gently mixed for 1 min. The cell mixture was diluted with 15 ml of HBSS, pelleted after centrifugation at 500 × g for 7 min and resuspended in 500 µl of 1xHBSS/1% BSA. Cells were quantitatively estimated using a hemacytometer.

### Neutrophil adhesion assay

6 cm tissue culture dishes were coated by incubating with either 1.5 ml of fresh mouse serum or various concentrations of poly-RGD peptides in a humidified incubator at 37 °C for 1.5 h. The coated plates were then washed twice with 2 ml of 1x HBSS/Ca<sup>2+</sup>/Mg<sup>2+</sup>/20 mM HEPES and resuspended in 1x HBSS/1% BSA to remove unbound peptides or serum components.

Freshly isolated bone marrow-derived neutrophils from either wild-type (WT) or JSP1-knockout mice were prepared. Half of the neutrophils were kept on ice as the "suspension" fraction, while the other half were plated onto either poly-RGD-coated plates and incubated at 37 °C for 15 min or fresh mouse serum-coated plates and incubated for 40 min to allow adhesion. After incubation, the non-adherent cells were removed by carefully aspirating the supernatant, and the adherent cells were lysed directly on the plate with 0.5 ml of lysis buffer.

### Protein extraction and immunoprecipitation

For immunoprecipitation (IP) experiments, cells were lysed in RIPA buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) supplemented with protease inhibitor cocktail. For immunoblotting, cells were lysed in NP-40 lysis buffer (LB). Lysis was performed in a cold room with gentle rocking for 30 min. Lysates were then centrifuged at 13,000 rpm for 15 min, and the supernatant was collected. Protein concentration was determined using the Bradford protein assay.

For IPs, 1 mg or 750 µg of lysate was incubated with 20 µl of Protein G agarose bead slurry overnight at 4 °C with continuous rocking. The next day, 10 µl of specific antibodies were added to the lysate-bead mixture and incubated at 4 °C for 90 min with rocking. Immunoprecipitates were collected

by centrifugation and washed three times with LB. Proteins were eluted by boiling with 2X SDS-PAGE loading buffer followed by immunoblotting analysis using the appropriate antibodies, including pSYK (Y323), HCK, pTyr 4G10, and pHCK (Y522).

### Statistical analysis

Data distributions were assessed for approximate normality prior to statistical analysis. All data are expressed as means  $\pm$  standard deviation (SD). Comparisons between two groups were performed using unpaired two-tailed Student's *t*-tests. Comparisons for more than two groups were analyzed using one-way or two-way ANOVA followed by a *post hoc* test as indicated in figure legends. Significance was set at  $p < 0.05$ .

### Data availability

The datasets generated during this study are available from the corresponding author upon reasonable request.

**Supporting information**—This article contains supporting information.

**Author contributions**—L. L. writing – original draft; L. L. and N. K. T. methodology; L. L. investigation; L. L. and N. K. T. conceptualization; N. K. T. writing – review & editing; N. K. T. supervision.

**Funding and additional information**—N. K. T. is the Caryl Boies Professor of Cancer Research at Cold Spring Harbor Laboratory. Research in the Tonks lab was supported by NIH grant R01CA53840, the CSHL Cancer Centre Support GrantCA45508, a grant from CART (Coins for Alzheimer's Research Trust), and the Hansen Foundation. L. L. is an Associate Professor of Biology at Molloy University. This research and writing were supported in part by a Faculty Scholarship and Academic Advancement Committee grant from Molloy University.

**Conflict of interest**—The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: N. K. T. is a member of the Scientific Advisory Board of DepYmed Inc. and Anavo Therapeutics. L. L. declares that she has no conflicts of interest.

**Abbreviations**—The abbreviations used are: CDKs, cyclin-dependent kinases; DUSPs, dual-specificity phosphatases; EMT, epithelial-to-mesenchymal transition; ER-alpha, estrogen receptor-alpha; HBSS, Hank's balanced salt solution; HCC, hepatocellular carcinoma; JNK, c-JUN N-terminal kinase; JSP1, JNK-stimulatory phosphatase 1; KO, knockout; LPS, lipopolysaccharide; LSR, local Shwartzman reaction; MAPK, Mitogen-activated protein kinase; NSCLC, non-small cell lung cancer; PTP, protein tyrosine phosphatase; TCR, T cell receptor; TNF, tumor necrosis factor-alpha; WT, Wild-type.

### References

- Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., *et al.* (2019) A comprehensive review on MAPK: a promising therapeutic target in cancer. *Cancers* **11**, 1618
- Ma, Y., and Nicolet, J. (2023) Specificity models in MAPK cascade signaling. *FEBS Open. Bio.* **13**, 1177–1192
- Seternes, O. M., Kidger, A. M., and Keyse, S. M. (2019) Dual-specificity MAP kinase phosphatases in health and disease. *Biochim. Biophys. Acta Mol. Cell Res* **1866**, 124–143
- Chuang, H. C., and Tan, T. H. (2019) MAP4K family kinases and DUSP family phosphatases in T-Cell signaling and systemic lupus erythematosus. *Cells* **8**, 1433
- Tonks, N. K. (2006) Protein tyrosine phosphatases: from genes, to function, to disease. *Nat. Rev. Mol. Cell Biol.* **7**, 833–846
- Huang, C. Y., and Tan, T. H. (2012) DUSPs, to MAP kinases and beyond. *Cell Biosci.* **2**, 24
- Shen, Y., Luche, R., Wei, B., Gordon, M. L., Diltz, C. D., and Tonks, N. K. (2001) Activation of the Jnk signaling pathway by a dual-specificity phosphatase, JSP-1. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 13613–13618
- Chen, A. J., Zhou, G., Juan, T., Colicos, S. M., Cannon, J. P., Cabriera-Hansen, M., *et al.* (2002) The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway. *J. Biol. Chem.* **277**, 36592–36601
- Alonso, A., Merlo, J. J., Na, S., Kholod, N., Jaroszewski, L., Kharitonov, A., *et al.* (2002) Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). *J. Biol. Chem.* **277**, 5524–5528
- Alonso, A., Narisawa, S., Bogetz, J., Tautz, L., Hadzic, R., Huynh, H., *et al.* (2004) VHY, a novel myristoylated testis-restricted dual specificity protein phosphatase related to VHX. *J. Biol. Chem.* **279**, 32586–32591
- Schwertassek, U., Buckley, D. A., Xu, C. F., Lindsay, A. J., McCaffrey, M. W., Neubert, T. A., *et al.* (2010) Myristoylation of the dual-specificity phosphatase c-JUN N-terminal kinase (JNK) stimulatory phosphatase 1 is necessary for its activation of JNK signaling and apoptosis. *FEBS J.* **277**, 2463–2473
- Ju, A., Cho, Y. C., Kim, B. R., Park, S. G., Kim, J. H., Kim, K., *et al.* (2016) Scaffold role of DUSP22 in ASK1-MKK7-JNK signaling pathway. *PLoS One* **11**, e0164259
- Chen, L., Su, H., Tao, Z., Liang, C., Liu, Z., Dong, Y., *et al.* (2024) DUSP22 ameliorates endothelial-to-mesenchymal transition in HUVECs through Smad2/3 and MAPK signaling pathways. *Cardiovasc. Ther.* **2024**, 5583961
- Li, J. P., Fu, Y. N., Chen, Y. R., and Tan, T. H. (2010) JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration. *J. Biol. Chem.* **285**, 5472–5478
- Ge, C., Tan, J., Dai, X., Kuang, Q., Zhong, S., Lai, L., *et al.* (2022) Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK. *Nat. Commun.* **13**, 5945
- Sekine, Y., Tsuji, S., Ikeda, O., Sato, N., Aoki, N., Aoyama, K., *et al.* (2006) Regulation of STAT3-mediated signaling by LMW-DSP2. *Oncogene* **25**, 5801–5806
- Sekine, Y., Ikeda, O., Hayakawa, Y., Tsuji, S., Imoto, S., Aoki, N., *et al.* (2007) DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. *Oncogene* **26**, 6038–6049
- Lee, S. H., Kim, H. J., Kim, S. W., Lee, H., Jung, D. W., and Williams, D. R. (2025) Modulating phosphatase DUSP22 with BML-260 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression. *EMBO Mol. Med.* **17**, 1259–1288
- Mu, X., Yu, C., Zhao, Y., Hu, X., Wang, H., He, Y., *et al.* (2024) Exosomal miR-1228-5p down-regulates DUSP22 to promotes cell proliferation and migration in small cell lung cancer. *Life Sci.* **351**, 122787
- Chen, J., Kang, G., Lei, W., Li, J., Wang, H., Bi, Y., *et al.* (2024) DUSP22 suppresses tumor progression by directly dephosphorylating AKT in non-small cell lung cancer. *Mol. Carcinog* **63**, 314–325
- Lin, H. H., Chang, C. W., Liao, Y. T., Yeh, S. D., Lin, H. P., Ho, H. M., *et al.* (2024) DUSP22 inhibits lung tumorigenesis by suppression of EGFR/c-Met signaling. *Cell Death Discov.* **10**, 285
- Lin, H. P., Ho, H. M., Chang, C. W., Yeh, S. D., Su, Y. W., Tan, T. H., *et al.* (2019) DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis. *FASEB J.* **33**, 14653–14667

## JSP1 in vascular inflammation

23. Li, J. P., Yang, C. Y., Chuang, H. C., Lan, J. L., Chen, D. Y., Chen, Y. M., *et al.* (2014) The phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck. *Nat. Commun.* **5**, 3618
24. Shih, Y. C., Chen, H. F., Wu, C. Y., Ciou, Y. R., Wang, C. W., Chuang, H. C., *et al.* (2024) The phosphatase DUSP22 inhibits UBR2-mediated K63-ubiquitination and activation of Lck downstream of TCR signalling. *Nat. Commun.* **15**, 532
25. Chen, X., Fang, M., Hong, J., and Guo, Y. (2024) JNK pathway-associated phosphatase deficiency facilitates atherosclerotic progression by inducing T-Helper 1 and 17 polarization and inflammation in an ERK- and NF- $\kappa$ B pathway-dependent manner. *J. Atheroscler. Thromb.* **31**, 1460–1478
26. Chen, M. H., Chuang, H. C., Yeh, Y. C., Chou, C. T., and Tan, T. H. (2023) Dual-specificity phosphatases 22-deficient T cells contribute to the pathogenesis of ankylosing spondylitis. *BMC Med.* **21**, 46
27. Chuang, H. C., Chen, Y. M., Hung, W. T., Li, J. P., Chen, D. Y., Lan, J. L., *et al.* (2016) Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis. *Oncotarget* **7**, 57593–57605
28. Zhao, M., and Huang, X. (2019) Downregulation of JKAP is correlated with elevated disease risk, advanced disease severity, higher inflammation, and poor survival in sepsis. *J. Clin. Lab Anal.* **33**, e22945
29. Qian, C., Chen, J., Xu, X., Liu, Q., Gu, M., Lu, S., *et al.* (2022) Measurement of synovium and serum dual specificity phosphatase 22 level: their inter-correlation and potency as biomarkers in rheumatoid arthritis. *J. Clin. Lab. Anal.* **36**, e24111
30. Stetson, C. A., and Good, R. A. (1951) Studies on the mechanism of the Schwartzman-phenomenon; evidence for the participation of polymorphonuclear leucocytes in the phenomenon. *J. Exp. Med.* **93**, 49–63
31. Brozna, J. P. (1990) Schwartzman reaction. *Semin. Thromb. Hemost.* **16**, 326–332
32. Qian, F., Deng, J., Cheng, N., Welch, E. J., Zhang, Y., Malik, A. B., *et al.* (2009) A non-redundant role for MKP5 in limiting ROS production and preventing LPS-induced vascular injury. *EMBO J.* **28**, 2896–2907
33. Hirahashi, J., Mekala, D., Van Ziffle, J., Xiao, L., Saffaripour, S., Wagner, D. D., *et al.* (2006) Mac-1 signaling via Src-family and Syk kinases results in elastase-dependent thrombohemorrhagic vasculopathy. *Immunity* **25**, 271–283
34. Rohwedder, I., Kurz, A. R. M., Pruenster, M., Immler, R., Pick, R., Eggersmann, T., *et al.* (2020) Src family kinase-mediated vesicle trafficking is critical for neutrophil basement membrane penetration. *Hematologica* **105**, 1845–1856
35. Ruoslahti, E. (1996) RGD and other recognition sequences for integrins. *Annu. Rev. Cell Dev. Biol.* **12**, 697–715
36. Yan, S. R., Huang, M., and Berton, G. (1997) Signaling by adhesion in human neutrophils: activation of the p72syk tyrosine kinase and formation of protein complexes containing p72syk and Src family kinases in neutrophils spreading over fibrinogen. *J. Immunol.* **158**, 1902–1910
37. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brigitte, W. H., Weringer, E. J., *et al.* (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. *J. Biol. Chem.* **271**, 695–701
38. Sur, S., and Agrawal, D. K. (2016) Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies. *Mol. Cell Biochem.* **416**, 33–46
39. Yokota, T., Nara, Y., Kashima, A., Matsubara, K., Misawa, S., Kato, R., *et al.* (2007) Crystal structure of human dual specificity phosphatase, JNK stimulatory phosphatase-1, at 1.5 Å resolution. *Proteins* **66**, 272–278
40. Hammouda, M. B., Ford, A. E., Liu, Y., and Zhang, J. Y. (2020) The JNK signaling pathway in inflammatory skin disorders and cancer. *Cells* **9**, Review
41. Vacaru, A. M., and den, H. J. (2010) Serine dephosphorylation of receptor protein tyrosine phosphatase alpha in mitosis induces Src binding and activation. *Mol. Cell Biol.* **30**, 2850–2861
42. Sen, B., and Johnson, F. M. (2011) Regulation of SRC family kinases in human cancers. *J. Signal Transduct* **2011**, 865819
43. Kant, S., Standen, C. L., Morel, C., Jung, D. Y., Kim, J. K., Swat, W., *et al.* (2017) A protein scaffold coordinates SRC-mediated JNK activation in response to metabolic stress. *Cell Rep.* **20**, 2775–2783
44. Ju, A., and Cho, S. (2012) Inhibition of dual-specificity phosphatase 22 (DUSP22) by PRL-3 inhibitor I. *Bull. Korean Chem. Soc.* **33**, 3142–3144